Effects of GM-CSF and IFN-γ1b in Ovarian Cancer Treatment
Author Information
Author(s): Sachin M Apte, Saroj Vadhan-Raj, Lorenzo Cohen, Roland L Bassett, Ilyssa O Gordon, Charles F Levenback, Pedro T Ramirez, Stacie T Gallardo, Rebecca S Patenia, Michael E Garcia, Revathy B Iyer, Ralph S Freedman
Primary Institution: The University of Texas M.D. Anderson Cancer Center
Hypothesis
Does the combination of GM-CSF and IFN-γ1b enhance the immune response in patients with recurrent ovarian cancer receiving carboplatin?
Conclusion
The treatment regimen increased myeloid cells and platelets in ovarian cancer patients, but did not consistently enhance immune responses.
Supporting Evidence
- White blood cell, neutrophil, and monocyte counts increased significantly after treatment.
- Platelet counts increased significantly on day 9 of the second and third treatment courses.
- Quality of life measurements showed a decrease during treatment but returned to baseline after recovery.
Takeaway
This study tested a new treatment for ovarian cancer that uses special proteins to help the immune system fight the cancer, and it showed some positive effects.
Methodology
Patients received GM-CSF and IFN-γ1b before and after carboplatin treatment, with assessments of blood cell counts and immune responses.
Limitations
The study only reports preliminary results from the first three treatment courses and does not include long-term outcomes.
Participant Demographics
{"median_age":62,"race":{"White":22,"Hispanic":2,"Black":1},"performance_status":{"0":22,"1":1,"2":2}}
Statistical Information
P-Value
p ≤ .001
Statistical Significance
p ≤ .001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website